Quite right Nzak I got my EBITDAs and NPATs muddled up - strange but true, must be New Year blues.
So the NPAT figure of $10M deserves a higher multiple - probably 6,8 or 10. Yes there is risk involved - that is why I will leave it to individual investors to apply their own multiple but at multiples of 6, 8 or 10 the sp would be 7c, 10c and 12c respectively.
The main point here is that yes it is not producing - but once producing NPAT multiples would be in the mid teens which would be still at the lower band of the industry average.
So whether you use a DCF or multiple basis still appears a buy.
Yes - we do not know how many shares will be on issue, but read the previous announcements. Appears they have hybrid finance jacked up. Appears they also have option to issue shares to a cornerstone investor at a 'significant' premium to current prices.
Seems to add up to me, but respect your position.
Spozzie
- Forums
- ASX - By Stock
- EHR
- please correct me..
please correct me.., page-17
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EHR (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online